Replimune Group, Inc.

REPL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-313.9M $-247.3M $-215.8M $-174.3M $-118.0M $-80.9M $-52.6M $-30.8M
Depreciation & Amortization $3.3M $3.5M $2.7M $2.4M $2.1M $1.7M $533.0K $148.0K
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $32.3M $35.0M $34.1M $28.1M $24.3M $11.8M $7.7M $2.7M
Net Cash from Operating Activities $-280.3M $-192.3M $-185.5M $-128.1M $-82.2M $-61.4M $-60.6M $-25.4M
Investing Activities
Capital Expenditures $4.2M $6.7M $5.7M $2.3M $2.3M $2.4M $6.5M $2.6M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $310.8M $-23.8M $97.2M $-142.5M $-1.8M $-188.8M $-5.2M $-65.9M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $66.3M $252.4M $16.3M $311.3M $6.6M $372.5M $100.2M $101.4M
Net Change in Cash $97.9M $36.7M $-72.1M $40.6M $-76.6M $123.0M $34.2M $9.2M
Free Cash Flow $-284.6M $-198.9M $-191.1M $-130.3M $-84.5M $-63.8M $-67.1M $-28.0M
← Newer Page 1 of 2 Older →